Clinical Trial Update: Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating liposomal irinotecan with TAS-102 and bevacizumab for metastatic colorectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Lonsurf (trifluridine/tipiracil)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING